DV
Dividend Vision

ARGX — argenx SE

argenx SE (ARGX)

Total return is 3601.3% over the past 9.2 years, 3322.2 points ahead of SPY at 279.1%. Its deepest 1-year drawdown was 28.6%.

ARGX is an equity fund that tracks argenx SE, a Belgium-based biopharmaceutical company focused on immunology and rare disease treatments. As a single-stock holding rather than a diversified ETF, it does not generate dividend distributions and carries no reported expense ratio typical of traditional ETFs. This structure appeals primarily to investors seeking direct exposure to argenx's growth potential in the specialty pharmaceuticals sector rather than income-focused investors.

ARGX key facts

Asset type
Stock
Asset class
Equity
Inception date
05/18/2017
Distribution frequency
None
Last close
$851.29
Market cap
$52,939,825,152
Average volume
278700.0
Beta
-0.04
Payout ratio
0.0
P/E ratio
32.6665
Forward P/E
30.4878
EPS
$26.06